Establishment and characterization of a novel MDM2/MYCN-co-amplified neuroblastoma cell line, NBN-SHIM, established from a late recurrent stage MS tumor

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Neuroblastoma exhibits significant biological heterogeneity, necessitating in vitro models for each molecular subgroup.
• Understanding tumorigenesis and developing targeted therapies require models reflecting distinct molecular profiles.

Purpose of the Study:

• Establish a permanently growing cell line from a specific neuroblastoma subtype.
• Characterize the cell line and its parent tumor for histological, molecular, and cytogenetic features.
• Investigate the unique telomere maintenance mechanism in the established cell line.

Main Methods:

• Histological, molecular, cytogenetic, exome, and telomere analyses were performed.
• Established a permanently growing cell line (NBM-SHIM) from a recurrent tumor.
• Assessed gene amplification (MDM2, MYCN), copy number variations (CDK4, GLI2), and telomere maintenance mechanisms (TERT expression, C-circle assay).

Main Results:

• The recurrent tumor was MDM2-amplified but MYCN-nonamplified; the cell line NBM-SHIM showed amplification of both MDM2 and MYCN.
• High ploidy at CDK4 and GLI2 loci was identified in both the tumor and cell line.
• NBM-SHIM displayed an unusual telomere maintenance mechanism with low TERT expression despite MYCN amplification, suggesting alternative lengthening of telomeres.

Conclusions:

• The NBM-SHIM cell line, derived from a late-relapsed, MYCN-nonamplified, MDM2-amplified neuroblastoma with acquired MYCN amplification during culture, is a unique research tool.
• This cell line is valuable for studying neuroblastoma tumorigenesis, particularly the disrupted ARF-TP53-MDM2 pathway.
• It provides a platform for developing novel molecular targeted therapies for amplified MDM2 and CDK4 in neuroblastoma.